{{Drugbox
| IUPAC_name = Ethyl 1-ethyl-4-[2-(propan-2-ylidene)hydrazinyl]-1''H''-pyrazolo[3,4-b]pyridine-5-carboxylate
| image = Etazolate.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = [[Mouth|Oral]]

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7336
| CAS_number = 51022-77-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 3277
| ChemSpiderID = 3162
| ChEBI = 138502
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = I89Y79062L
| ChEMBL = 356388

<!--Chemical data-->
| C=14 | H=19 | N=5 | O=2 
| molecular_weight = 289.33 g/mol
| smiles = CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC
}}

'''Etazolate''' ('''SQ-20,009''', '''EHT-0202''') is an [[anxiolytic]] [[drug]] which is a [[pyrazolopyridine]] [[chemical derivative|derivative]] and has unique [[pharmacology|pharmacological]] properties.<ref name="isbn0-7514-0499-3">{{cite book |author1=Hall, Judith A. |author2=Morton, Ian | title = Concise dictionary of pharmacological agents: properties and synonyms | publisher = Kluwer Academic | location = | year = 1999 | pages = | isbn = 0-7514-0499-3 | oclc = | doi = | url = https://books.google.com/books?id=mqaOMOtk61IC&lpg=PA115&dq=etazolate&pg=PA115#v=onepage&q=etazolate&f=false}}</ref><ref name="pmid6132997">{{cite journal | author = Williams M | title = Anxioselective anxiolytics | journal = Journal of Medicinal Chemistry | volume = 26 | issue = 5 | pages = 619–28 |date=May 1983 | pmid = 6132997 | doi = 10.1021/jm00359a001| url = }}</ref><ref name="pmid449623">{{cite journal |vauthors=Williams M, Risley EA | title = Enhancement of the binding of 3H-diazepam to rat brain membranes in vitro by SQ 20009, A novel anxiolytic, gamma-aminobutyric acid (GABA) and muscimol | journal = Life Sciences | volume = 24 | issue = 9 | pages = 833–41 |date=February 1979 | pmid = 449623 | doi = 10.1016/0024-3205(79)90367-9| url = }}</ref> It acts as a [[positive allosteric modulator]] of the [[GABAA receptor|GABA<sub>A</sub> receptor]] at the [[barbiturate]] [[binding site]],<ref name="pmid8773466">{{cite journal |vauthors=Zezula J, Slany A, Sieghart W | title = Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits | journal = European Journal of Pharmacology | volume = 301 | issue = 1–3 | pages = 207–14 |date=April 1996 | pmid = 8773466 | doi = 10.1016/0014-2999(96)00066-0| url = }}</ref><ref name="isbn0-8493-8386-2">{{cite book |author1=Remington, Gary |author2=Baskys, Andrius | title = Brain mechanisms and psychotropic drugs | publisher = CRC Press | location = Boca Raton | year = 1996 | pages = | isbn = 0-8493-8386-2 | oclc = | doi = | url = https://books.google.com/books?id=SPEIn0S6aK8C&lpg=PA109&dq=etazolate&pg=PA109#v=onepage&q=etazolate&f=false}}</ref><ref name="isbn3-540-66127-1">{{cite book |author1=M. Mishina |author2=Kurachi, Yoshihisa | title = Pharmacology of ionic channel function: activators and inhibitors | publisher = Springer | location = Berlin | year = 2000 | pages = | isbn = 3-540-66127-1 | oclc = | doi = | url = https://books.google.com/books?id=t7i4yNiXiFMC&lpg=PA503&dq=etazolate&pg=PA503#v=onepage&q=etazolate&f=false}}</ref><ref name="isbn3-7643-1837-6">{{cite book | title = Progress in Drug Research / Volume 31 (Progress in Drug Research) | publisher = Birkhauser | location = Boston | year = 1987 | page = 526 | isbn = 3-7643-1837-6 | oclc = | doi = | url = https://books.google.com/books?id=gx6dwxmlQwMC&lpg=PA233&dq=etazolate&pg=PA225#v=onepage&q=etazolate&f=false}}</ref> as an [[adenosine]] [[receptor antagonist|antagonist]] of the [[adenosine A1 receptor|A<sub>1</sub>]] and [[Adenosine A2 receptor (disambiguation)|A<sub>2</sub> subtypes]],<ref name="pmid3283781">{{cite journal |vauthors=Williams M, Jarvis MF | title = Adenosine antagonists as potential therapeutic agents | journal = Pharmacology, Biochemistry, and Behavior | volume = 29 | issue = 2 | pages = 433–41 |date=February 1988 | pmid = 3283781 | doi = 10.1016/0091-3057(88)90182-7| url = }}</ref> and as a [[phosphodiesterase inhibitor]] selective for the [[PDE4]] [[isoform]].<ref name="pmid4345859">{{cite journal |vauthors=Chasin M, Harris DN, Phillips MB, Hess SM | title = 1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)--a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases | journal = [[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] | volume = 21 | issue = 18 | pages = 2443–50 |date=September 1972 | pmid = 4345859 | doi = 10.1016/0006-2952(72)90414-5| url = http://linkinghub.elsevier.com/retrieve/pii/0006-2952(72)90414-5}}</ref><ref name="pmid9177268">{{cite journal |vauthors=Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM | title = Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D | journal = Biochemical and Biophysical Research Communications | volume = 234 | issue = 2 | pages = 320–4 |date=May 1997 | pmid = 9177268 | doi = 10.1006/bbrc.1997.6636 | url = http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(97)96636-5}}</ref><ref name="isbn0-521-80261-X">{{cite book |author1=Gresele, Paolo |author2=Gresele, P. | title = Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics | publisher = Cambridge University Press | location = Cambridge, UK | year = 2002 | pages = | isbn = 0-521-80261-X | oclc = | doi = | url = https://books.google.com/books?id=W1O-rgRYSdEC&lpg=PA294&dq=etazolate%20%22PDE4%22&pg=PA294#v=onepage&q=etazolate%20%22PDE4%22&f=false}}</ref> It is currently in [[clinical trial]]s for the treatment of [[Alzheimer's disease]].<ref name="urlPipeline | ExonHit">{{cite web | url = http://www.exonhit.com/therapeutics/pipeline#eht_0202 | title = Pipeline &#124; ExonHit | work = | accessdate = August 2010}}</ref>

==Synthesis==
[[File:Cartazolate&Etazolate synthesis.png|thumb|center|700px|Cartazolate and Etazolate synthesis: E.R. SQUIBB & SONS, INC., NEW YORK, N.Y., US. {{Cite patent|DE|2123318}}]]

== See also ==
* [[Cartazolate]]
* [[ICI-190,622]]
* [[Tracazolate]]

== References ==
{{Reflist}}

{{Anxiolytics}}
{{GABAAR PAMs}}
{{Adenosinergics}}
{{Phosphodiesterase inhibitors}}

[[Category:Anxiolytics]]
[[Category:Pyrazolopyridines]]
[[Category:Hydrazones]]
[[Category:PDE4 inhibitors]]
[[Category:Ethyl esters]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Adenosine receptor antagonists]]